Disc Medicine (NASDAQ:IRON) Given Outperform Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Disc Medicine (NASDAQ:IRON) in a research report sent to investors on Tuesday morning,RTT News reports. The brokerage currently has a $90.00 target price on the stock, up from their previous target price of $83.00. Wedbush also issued estimates for Disc Medicine’s FY2026 earnings at ($3.96) EPS, FY2027 earnings at $2.64 EPS, FY2028 earnings at $7.51 EPS and FY2029 earnings at $12.05 EPS.

Several other analysts also recently weighed in on IRON. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Stifel Nicolaus lifted their target price on Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research note on Tuesday, October 15th. Scotiabank lifted their price objective on Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a report on Monday, December 9th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine currently has an average rating of “Buy” and a consensus target price of $88.50.

Disc Medicine Stock Down 2.6 %

IRON opened at $56.99 on Tuesday. The business has a fifty day moving average of $62.66 and a 200 day moving average of $53.72. The stock has a market cap of $1.70 billion, a P/E ratio of -14.32 and a beta of 0.75. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. Equities analysts anticipate that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In related news, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the transaction, the chief executive officer now owns 72,065 shares in the company, valued at approximately $4,757,010.65. The trade was a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William Richard White sold 7,136 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The disclosure for this sale can be found here. Insiders sold a total of 85,758 shares of company stock valued at $5,400,990 in the last three months. 4.24% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Disc Medicine

A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its stake in shares of Disc Medicine by 4.8% in the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after purchasing an additional 83,731 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in Disc Medicine by 123.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after buying an additional 969,834 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Disc Medicine by 53.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after buying an additional 357,730 shares in the last quarter. Logos Global Management LP acquired a new stake in shares of Disc Medicine during the 2nd quarter valued at approximately $41,690,000. Finally, State Street Corp boosted its stake in shares of Disc Medicine by 39.7% during the 3rd quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after acquiring an additional 235,115 shares in the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.